GLP-1 Market
LLY $1157.08 ▼ -2.3% NVO $37.91 ▼ -1.0% PFE $28.52 ▼ -0.7% VKTX $32.60 ▲ +2.5% KLRA $11.42 ▲ +3.9% GPCR $31.27 ▼ -4.3% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DPP-4 inhibitor

Company
Chong Kun Dang Pharmaceutical
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
10 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

10 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for DPP-4 inhibitor and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06528405

    The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

    Not yet reported National Taiwan University Hospital 264 participants Est. completion 2027-12 1 site
    Other conditions: Acute Kidney Injury
    View official trial listing →
  • Recruiting NCT NCT06838286

    Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

    Chong Kun Dang Pharmaceutical 10000 participants Est. completion 2029-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06875193

    DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

    Not yet reported Dong Wha Pharmaceutical Co. Ltd. 196 participants Est. completion 2025-12-31 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Recruiting NCT NCT06972732

    A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

    Not yet reported Boryung Pharmaceutical Co., Ltd 204 participants Est. completion 2026-10-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07314684

    GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

    Not yet reported Federico II University 80 participants Est. completion 2027-03-08 2 sites
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07365592

    Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

    Not yet reported, Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 138 participants Est. completion 2029-12-31 1 site
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT07374328

    Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Second Affiliated Hospital of Guangzhou Medical University 240 participants Est. completion 2026-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07614230

    SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

    Not yet reported Junjie Yang 144 participants Est. completion 2028-12-31 2 sites
    Type 2 diabetesCardiovascular disease Other conditions: Atherosclerosis
    View official trial listing →
  • Recruiting NCT NCT07634380

    Sitagliptin With Pembro in RCC and Melanoma

    Not yet reported Fernando Maciel Barbosa 64 participants Est. completion 2031-04-10 1 site
    Other conditions: Advanced Renal Cell Carcinoma, Advanced Melanoma
    View official trial listing →
  • Recruiting NCT NCT07717242

    Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80 participants Est. completion 2029-01-31 1 site Stand-alone
    Other conditions: Bladder Urothelial Carcinoma, Bladder Cancer
    View official trial listing →
  • Completed NCT NCT00111631

    A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 218 participants Est. completion 2006-10 37 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00111670

    A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 291 participants Est. completion 2006-07 40 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00370942

    GW823093C For The Treatment Of Type 2 Diabetes Mellitus

    Not yet reported GlaxoSmithKline 159 participants Est. completion 2006-11-25 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00411411

    Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes

    Not yet reported University Hospital, Gentofte, Copenhagen 49 participants Est. completion 2009-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00451113

    Sitagliptin in the Elderly

    Not yet reported University of British Columbia 12 participants Est. completion 2012-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00551590

    Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus

    Not yet reported Ludwig-Maximilians - University of Munich 24 participants Est. completion 2011-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00572650

    Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

    Not yet reported Novartis 29 participants Est. completion 2007-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00575588

    52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

    Not yet reported AstraZeneca 891 participants Est. completion 2010-08 94 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00614939

    Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

    Not yet reported AstraZeneca 572 participants Est. completion 2010-03 74 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00661362

    Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 570 participants Est. completion 2009-09 30 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00676338

    Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    Not yet reported AstraZeneca 820 participants Est. completion 2011-01 106 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00690638

    Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

    Not yet reported Phenomix 480 participants Est. completion 2010-04 62 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00698932

    Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control

    Not yet reported AstraZeneca 568 participants Est. completion 2009-10 30 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT00699322

    Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress

    Not yet reported The Catholic University of Korea 36 participants Est. completion 2010-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00721552

    Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome

    Not yet reported Amsterdam UMC, location VUmc 82 participants Est. completion 2012-06 1 site
    Other conditions: Diabetes Mellitus, Steroid Diabetes, Glucocorticoid-induced Diabetes, Beta-cell Function
    View official trial listing →
  • Completed NCT NCT00770302

    Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin

    Not yet reported AstraZeneca 34 participants Est. completion 2008-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00813228

    Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 76 participants Est. completion 2019-11-26 1 site
    Type 2 diabetes Other conditions: Diabetes Mellitus Type 1
    View official trial listing →
  • Status unknown NCT NCT00836940

    A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus

    Not yet reported Glenmark Pharmaceuticals Europe Ltd. (R&D) 480 participants Est. completion 2009-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00850239

    Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

    Not yet reported Phenomix 700 participants Est. completion 2010-12 97 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00853944

    Effect of Sitagliptin on Graft Function Following Islet Transplantation

    Not yet reported University of British Columbia 12 participants Est. completion 2013-11-01 1 site
    Other conditions: Islet Transplantation
    View official trial listing →
  • Terminated NCT NCT00865592

    Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Phenomix 450 participants Est. completion 2011-03 68 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00881543

    "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"

    Not yet reported University of Sao Paulo General Hospital 45 participants Est. completion 2011-10 1 site
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT00888238

    A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

    Not yet reported Merck Sharp & Dohme LLC 12 participants Est. completion 2009-07-21
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00918879

    Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control

    Not yet reported AstraZeneca 213 participants Est. completion 2010-07 9 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00958269

    Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

    Not yet reported Phenomix 360 participants Est. completion 2011-11 43 sites
    Type 2 diabetes Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT00964184

    Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population

    Not yet reported Diabetes Foundation, India 133 participants Est. completion 2015-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00968708

    Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

    Not yet reported Takeda 5380 participants Est. completion 2013-06 908 sites
    Type 2 diabetes Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Completed NCT NCT00971659

    Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

    Not yet reported Profil Institut für Stoffwechselforschung GmbH 48 participants Est. completion 2008-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00984867

    Dapagliflozin DPPIV Inhibitor add-on Study

    Not yet reported AstraZeneca 833 participants Est. completion 2011-09 88 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00998686

    Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

    Not yet reported Phenomix 650 participants Est. completion 2011-11 44 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01006018

    DPP-4 Inhibition and TZD for DM Prevention

    Not yet reported Emory University 3 participants Est. completion 2011-12 2 sites
    Other conditions: Prediabetic State
    View official trial listing →
  • Completed NCT NCT01009580

    Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 447 participants Est. completion 2010-08-23 53 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Withdrawn NCT NCT01038648

    Sitagliptin in Prevention of Type 2 Diabetes Mellitus

    Not yet reported India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals Est. completion 2014-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01046110

    Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

    Not yet reported Novo Nordisk A/S 458 participants Est. completion 2010-11 93 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT01101945

    Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Phenomix 339 participants Est. completion 2010-03 55 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106651

    A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

    Not yet reported Janssen Research & Development, LLC 716 participants Est. completion 2013-05 86 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01106677

    The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

    Not yet reported Janssen Research & Development, LLC 1284 participants Est. completion 2012-05 125 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01122641

    The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

    Not yet reported Royal Devon and Exeter NHS Foundation Trust 15 participants Est. completion 2014-08-01 1 site
    Other conditions: Insulin Resistance, Microvascular Disease
    View official trial listing →
  • Completed NCT NCT01137812

    The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

    Not yet reported Janssen Research & Development, LLC 756 participants Est. completion 2012-03 184 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01155284

    Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

    Not yet reported Sanford Health 70 participants Est. completion 2015-03 3 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT01176708

    Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion

    Not yet reported University Hospital, Gentofte, Copenhagen 30 participants Est. completion 2012-12 1 site
    Other conditions: Liver Transplantation
    View official trial listing →
  • Status unknown NCT NCT01176760

    Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects

    Not yet reported University Hospital, Gentofte, Copenhagen 30 participants Est. completion 2012-12 1 site
    Other conditions: Vagotomy, Truncal
    View official trial listing →
  • Completed NCT NCT01189890

    Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

    Not yet reported Merck Sharp & Dohme LLC 480 participants Est. completion 2012-10-31
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01192659

    Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

    AstraZeneca 16492 participants Est. completion 2015-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01235819

    Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

    Not yet reported Command Hospital, India 20 participants Est. completion 2011-09 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01242228

    A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

    Not yet reported Astellas Pharma Inc 106 participants Est. completion 2012-06-06 6 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01257464

    Sitagliptin in Cystic Fibrosis-Related Diabetes

    Not yet reported University of British Columbia 3 participants Est. completion 2012-06 1 site
    Other conditions: Cystic Fibrosis
    View official trial listing →
  • Completed NCT NCT01272583

    Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 16 participants Est. completion 2012-10 1 site
    Other conditions: Type 1 Diabetes, Hypoglycemia
    View official trial listing →
  • Completed NCT NCT01333592

    Long-term Study of KAD-1229 in Type 2 Diabetes Patients

    Not yet reported Kissei Pharmaceutical Co., Ltd. 136 participants Est. completion 2012-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01337440

    Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

    Not yet reported Kanazawa University 20 participants Est. completion 2013-03 1 site
    Type 2 diabetes Other conditions: Chronic Liver Disease
    View official trial listing →
  • Status unknown NCT NCT01339143

    Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

    Not yet reported Korea University Anam Hospital 80 participants Est. completion 2013-05 1 site
    Other conditions: Diabetes Mellitus, Oxidative Stress
    View official trial listing →
  • Completed NCT NCT01368081

    Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

    Not yet reported Boehringer Ingelheim 1162 participants Est. completion 2013-04 87 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01377935

    Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

    AstraZeneca 113505 participants Est. completion 2015-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01378117

    Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

    Not yet reported Emory University 90 participants Est. completion 2012-06 2 sites
    Type 2 diabetes Other conditions: Hospitalization, Hyperglycemia
    View official trial listing →
  • Completed NCT NCT01413542

    Pharmacogenetics of Ace Inhibitor-Associated Angioedema

    Not yet reported Vanderbilt University 44 participants Est. completion 2014-07 1 site
    Other conditions: Hypertension, Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT01449747

    Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus

    Not yet reported The Catholic University of Korea 24 participants Est. completion 2015-07 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01452113

    Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy

    Not yet reported University Hospital, Toulouse 21 participants Est. completion 2013-03 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Withdrawn NCT NCT01503008

    Proteus Sustained Behavior Change Study

    Not yet reported Proteus Digital Health, Inc. Est. completion 2012-08 2 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01545024

    Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus

    Nagaoka Red Cross Hospital 60 participants Est. completion 2013-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01559025

    Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

    Not yet reported Federal University of São Paulo 44 participants Est. completion 2017-03 1 site
    Other conditions: Type 1 Diabetes, Insulin Dependent Diabetes, Juvenile Onset Diabetes Mellitus, Autoimmune Diabetes
    View official trial listing →
  • Status unknown NCT NCT01568125

    Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus

    Nagaoka Red Cross Hospital 100 participants Est. completion 2014-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01588587

    DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

    Nagaoka Red Cross Hospital 500 participants Est. completion 2017-12 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01610154

    Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

    Not yet reported Guangwei Li 85 participants Est. completion 2015-06 1 site
    Other conditions: Insulin Secretion, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT01617824

    Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

    Not yet reported University of Padova 45 participants Est. completion 2014-12 1 site
    Type 2 diabetes Other conditions: Chronic Renal Failure
    View official trial listing →
  • Status unknown NCT NCT01642108

    Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus

    Not yet reported Niigata Medical Center 40 participants Est. completion 2013-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01660386

    Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"

    Not yet reported Shanghai Jiao Tong University School of Medicine 12 participants Est. completion 2013-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01677104

    The Microvascular Function of GLP-1 and Its Analogues

    Not yet reported Katarina Kos 63 participants Est. completion 2014-07 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01744236

    SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

    Not yet reported Amsterdam UMC, location VUmc 70 participants Est. completion 2015-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01767389

    Glucagon-like Peptide (GLP) Utilization and Safety

    GlaxoSmithKline 1 participants Est. completion 2013-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01794143

    A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

    Not yet reported GRADE Study Group 7850 participants Est. completion 2021-04-30 36 sites
    Type 2 diabetes Other conditions: Comparative Effectiveness of Glycemia-lowering Medications
    View official trial listing →
  • Completed NCT NCT01798238

    Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

    Not yet reported Handok Inc. 142 participants Est. completion 2014-05 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01805830

    Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

    Not yet reported Handok Inc. 189 participants Est. completion 2013-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01822548

    Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

    Not yet reported Azienda Ospedaliero-Universitaria di Parma 64 participants Est. completion 2015-01 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01845831

    Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

    Not yet reported Emory University 292 participants Est. completion 2016-04 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01847144

    MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes

    Not yet reported Royal Devon and Exeter NHS Foundation Trust 143 participants Est. completion 2015-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01856907

    Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

    Not yet reported Woman's 36 participants Est. completion 2017-09-28 1 site
    Other conditions: Disorder of Glucose Regulation
    View official trial listing →
  • Completed NCT NCT01859793

    Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

    Not yet reported Medical College of Wisconsin 38 participants Est. completion 2016-07 1 site
    Other conditions: Diabetes, Atherosclerosis
    View official trial listing →
  • Completed NCT NCT01890993

    Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

    Novo Nordisk A/S 952 participants Est. completion 2014-06 4 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01894568

    A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

    Not yet reported Eli Lilly and Company 388 participants Est. completion 2015-04 31 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01901861

    Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes

    Not yet reported Lund University 12 participants Est. completion 2015-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01922817

    DPP4inhibitors in Type 1 Diabetes

    Not yet reported University of Dundee 28 participants Est. completion 2014-04 1 site
    Other conditions: Type 1 Diabetes, Hypoglycaemia
    View official trial listing →
  • Completed NCT NCT01930188

    Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 1231 participants Est. completion 2015-10-12 141 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01937598

    Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D

    Not yet reported Michael A. Nauck 16 participants Est. completion 2015-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01944618

    forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

    AstraZeneca 5000 participants Est. completion 2015-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01972542

    The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk

    Not yet reported Seoul National University Bundang Hospital 80 participants Est. completion 2015-08 1 site
    Prediabetes Other conditions: Diabetes
    View official trial listing →
  • Status unknown NCT NCT01974544

    Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines

    Not yet reported Pontificia Universidad Catolica de Chile 150 participants Est. completion 2016-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01990469

    Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

    Not yet reported LG Life Sciences 219 participants Est. completion 2015-04 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02009488

    Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Janssen Research & Development, LLC 59 participants Est. completion 2017-01-03 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02015299

    Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes

    Not yet reported dr. DJ Mulder 45 participants Est. completion 2016-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT02015780

    Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

    Not yet reported Takeda Est. completion 2016-01 30 sites
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Terminated NCT NCT02015910

    Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

    Not yet reported Georgetown University 1 participants Est. completion 2015-01 1 site
    Other conditions: Type II Diabetes
    View official trial listing →
  • Completed NCT NCT02022007

    Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

    Not yet reported Woman's 38 participants Est. completion 2016-10 1 site
    Other conditions: Polycystic Ovary Syndrome, Disorder of Glucose Regulation
    View official trial listing →
  • Completed NCT NCT02024477

    Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

    Not yet reported George Washington University 42 participants Est. completion 2017-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02027753

    Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

    Not yet reported Sanofi 109 participants Est. completion 2015-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02029846

    Glycemia in Diabetic Elders Trial

    Not yet reported Johns Hopkins University 2 participants Est. completion 2017-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02041234

    Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

    Not yet reported Khoo Teck Puat Hospital 40 participants Est. completion 2022-06 1 site
    Other conditions: Type II Diabetes in Subjects BMI 27 to 32
    View official trial listing →
  • Completed NCT NCT02043054

    Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)

    Not yet reported University of Leicester 90 participants Est. completion 2017-09-29 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Terminated NCT NCT02048904

    Use of Sitagliptin to Decrease Microalbuminuria

    Not yet reported University of Missouri-Columbia 142 participants Est. completion 2016-06 1 site
    Type 2 diabetes Other conditions: Microalbuminuria
    View official trial listing →
  • Completed NCT NCT02061969

    ADA Linagliptin in Long Term Care

    Not yet reported Emory University 140 participants Est. completion 2017-04-10 4 sites
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02089438

    DPP-4 Inhibition, Incretins and Islet Function

    Not yet reported Lund University 24 participants Est. completion 2017-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02092597

    Safety Evaluation of Adverse Reactions in Diabetes

    Not yet reported Charles University, Czech Republic 42 participants Est. completion 2016-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02104804

    Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

    Not yet reported AstraZeneca 953 participants Est. completion 2016-02-26 11 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02105792

    PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

    Royal Devon and Exeter NHS Foundation Trust 820 participants Est. completion 2016-05 5 sites
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02106104

    Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

    Not yet reported Amsterdam UMC, location VUmc 48 participants Est. completion 2016-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02109978

    RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

    Royal Devon and Exeter NHS Foundation Trust 562 participants Est. completion 2015-05 3 sites
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02130687

    Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

    Not yet reported Vanderbilt University 106 participants Est. completion 2020-08 1 site
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02140645

    Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

    Boehringer Ingelheim 166613 participants Est. completion 2015-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02148978

    Cystic Fibrosis Related Diabetes

    Not yet reported Ram Weiss 30 participants 1 site
    Other conditions: Cystic Fibrosis
    View official trial listing →
  • Completed NCT NCT02150707

    The Differential Effects of Diabetes Therapy on Inflammation

    University College Dublin 17 participants Est. completion 2015-12 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Completed NCT NCT02180334

    The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

    Not yet reported Seoul National University Hospital 12 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02182895

    Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

    Not yet reported Brigham and Women's Hospital 72 participants Est. completion 2017-02 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02186080

    Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia

    Not yet reported Seoul National University Hospital 10 participants Est. completion 2015-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02188186

    Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients

    Not yet reported Seoul National University Bundang Hospital 200 participants Est. completion 2018-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02192853

    Correlation Between Plasma- and Endothelial DPP-4 Activity

    Not yet reported University Hospital, Gentofte, Copenhagen 20 participants Est. completion 2014-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02207374

    A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 601 participants Est. completion 2016-02-27 43 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02219750

    Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients

    Not yet reported Mackay Memorial Hospital 181 participants Est. completion 2016-08 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02231021

    The Practical Evidence of Antidiabetic Combination Therapy in Korea

    Not yet reported Kun-Ho Yoon 216 participants Est. completion 2019-01-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02244164

    Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

    Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 site
    Type 2 diabetes Other conditions: Incretinomimetics, Pancreas
    View official trial listing →
  • Status unknown NCT NCT02250872

    Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

    Not yet reported, Not yet reported Seoul National University Bundang Hospital 182 participants Est. completion 2018-06 1 site
    Other conditions: Cancer, Cisplatin Adverse Reaction
    View official trial listing →
  • Withdrawn NCT NCT02263677

    Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI

    Not yet reported University of Missouri-Columbia Est. completion 2016-01 1 site
    Type 2 diabetes Other conditions: Non-alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT02273050

    Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

    Not yet reported AstraZeneca 1136 participants Est. completion 2016-08 17 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02285985

    Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

    Not yet reported Phoenix VA Health Care System 103 participants Est. completion 2019-10-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02307695

    The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes

    Not yet reported Nanjing Medical University 184 participants Est. completion 2017-03 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02312063

    Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes

    Not yet reported Kansai Electric Power Hospital 48 participants Est. completion 2016-05 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02312375

    Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients

    Not yet reported Seoul National University Hospital 46 participants Est. completion 2017-03 1 site
    Other conditions: Diabetes Mellitus, Hypertension
    View official trial listing →
  • Completed NCT NCT02312427

    DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure

    Not yet reported Mitsui Memorial Hospital 10 participants Est. completion 2016-03 1 site Stand-alone
    Heart failure Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02314637

    Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

    Not yet reported Tanabe Pharma Corporation 240 participants Est. completion 2011-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02330406

    Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

    Not yet reported Institute for Clinical Effectiveness, Japan 353 participants Est. completion 2019-03 1 site
    Other conditions: Dipeptidyl-Peptidase 4 Inhibitors, LDL Cholesterol, Glycosylated Hemoglobin, Diabetes Mellitus, Coronary Disease
    View official trial listing →
  • Completed NCT NCT02333591

    Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

    Not yet reported Mette Zander 25 participants Est. completion 2018-06 1 site
    Other conditions: Coronary Microvascular Dysfunction
    View official trial listing →
  • Completed NCT NCT02338921

    Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

    Not yet reported Seoul National University Bundang Hospital 78 participants Est. completion 2021-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02365233

    Fatty Liver Study in Patients With Type II Diabetes

    Not yet reported The University of Texas Medical Branch, Galveston 5 participants Est. completion 2016-12-31 1 site
    Other conditions: Type II Diabetes, Nonalcoholic Fatty Liver
    View official trial listing →
  • Completed NCT NCT02377388

    DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

    Not yet reported University of Sao Paulo General Hospital 74 participants Est. completion 2020-02-28 1 site
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT02386943

    Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

    Not yet reported Shanghai Jiao Tong University School of Medicine 12 participants Est. completion 2015-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02406443

    The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

    Not yet reported University Health Network, Toronto 36 participants Est. completion 2017-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02407899

    Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes

    Not yet reported Second Xiangya Hospital of Central South University 300 participants Est. completion 2020-12-31 39 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02442817

    Linagliptin and Mesenchymal Stem Cells: A Pilot Study

    Not yet reported University of Nevada, Reno 10 participants Est. completion 2018-03-02 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02449330

    Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

    Not yet reported National Cerebral and Cardiovascular Center, Japan 936 participants Est. completion 2023-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02456428

    Incretin-based Drugs and the Risk of Heart Failure

    Canadian Network for Observational Drug Effect Studies, CNODES 1499650 participants Est. completion 2015-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02470039

    Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

    Not yet reported Novo Nordisk A/S 50 participants Est. completion 2015-12-31 2 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02475499

    Incretin-based Drugs and Pancreatic Cancer

    Canadian Network for Observational Drug Effect Studies, CNODES 886172 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02476760

    Incretin-based Drugs and Acute Pancreatitis

    Canadian Network for Observational Drug Effect Studies, CNODES 1417914 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02513771

    Sitagliptin for Reducing Inflammation and Immune Activation

    Not yet reported Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 90 participants Est. completion 2017-01-10 16 sites
    Other conditions: HIV-1 Infection
    View official trial listing →
  • Status unknown NCT NCT02528019

    Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

    Not yet reported Kurume University 100 participants Est. completion 2018-08 1 site
    Other conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
    View official trial listing →
  • Status unknown NCT NCT02606617

    A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes

    Not yet reported Third Military Medical University 200 participants Est. completion 2016-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02607410

    Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D

    Not yet reported University of Sao Paulo General Hospital 40 participants Est. completion 2014-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02616666

    A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

    Not yet reported University of Liverpool 632 participants Est. completion 2025-12-12 132 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02620592

    Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

    Not yet reported Zydus Lifesciences Limited 84 participants Est. completion 2015-10 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02639637

    Effect of DPP4 Inhibition on Vasoconstriction

    Not yet reported Vanderbilt University 18 participants Est. completion 2017-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02653131

    The Use of DPP-4 Inhibitors in Short Bowel Syndrome

    Not yet reported Stanley Dudrick's Memorial Hospital 8 participants Est. completion 2020-04 1 site Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT02653209

    TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

    Not yet reported Royal Devon and Exeter NHS Foundation Trust 525 participants Est. completion 2021-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02686476

    Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

    Not yet reported Medanta, The Medicity, India 100 participants Est. completion 2017-12 1 site
    Other conditions: Non Alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT02694575

    The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes

    University of Leicester 241 participants Est. completion 2018-08-31 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT02730377

    Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 1991 participants Est. completion 2019-08-12 232 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02737657

    An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan

    Janssen-Cilag International NV 379 participants Est. completion 2016-09 9 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02741687

    Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

    Not yet reported Emory University 80 participants Est. completion 2017-04 2 sites
    Other conditions: Hyperglycemia
    View official trial listing →
  • Completed NCT NCT02749890

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

    Not yet reported Sanofi 321 participants Est. completion 2018-05 61 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02752828

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

    Not yet reported Sanofi 521 participants Est. completion 2018-03-12 113 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02754219

    Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

    Not yet reported Dong-A ST Co., Ltd. 24 participants Est. completion 2018-01-19 1 site
    Other conditions: Liver Dysfunction
    View official trial listing →
  • Completed NCT NCT02792400

    The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

    Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2018-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02798172

    The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

    Not yet reported Fourth People's Hospital of Shenyang 81 participants Est. completion 2015-08 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02802644

    The Effect of DPP4 Inhibitor on Vasclular Healing

    Not yet reported Chung-Ang University 66 participants 6 sites Stand-alone
    Type 2 diabetes Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Completed NCT NCT02803892

    Monotherapy With Rapamycin in Long-standing Type 1 Diabetes

    Not yet reported Piemonti Lorenzo 55 participants Est. completion 2019-03 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02851745

    Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

    Not yet reported Heart Care Foundation 188 participants Est. completion 2019-07-02 19 sites
    Type 2 diabetes Other conditions: Left Ventricular Systolic Dysfunction
    View official trial listing →
  • Completed NCT NCT02853630

    A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

    Not yet reported India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals 203 participants Est. completion 2018-12 6 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02857764

    Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

    Janssen Research & Development, LLC 127690 participants Est. completion 2017-06-30
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02864914

    Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

    Boehringer Ingelheim 333580 participants Est. completion 2022-07-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02940184

    GLP-1 Signaling in Truncally Vagotomized Subjects

    Not yet reported University of Copenhagen 24 participants Est. completion 2018-10 1 site Stand-alone
    Other conditions: Physiology
    View official trial listing →
  • Completed NCT NCT02941445

    Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss

    Not yet reported University Medical Centre Ljubljana 24 participants Est. completion 2016-08
    Other conditions: Polycystic Ovary Syndrome, Body Weight
    View official trial listing →
  • Completed NCT NCT02946541

    A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin

    Not yet reported Dong-A ST Co., Ltd. 160 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02954692

    A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

    Not yet reported Sanofi 112 participants Est. completion 2017-12-22 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03014479

    Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

    Not yet reported Takeda 219 participants Est. completion 2017-10-21 27 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03050619

    Characteristics of Empagliflozin Initiators

    Boehringer Ingelheim 31908 participants Est. completion 2016-10-14 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03122041

    Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

    Not yet reported University Medical Centre Ljubljana 30 participants Est. completion 2016-11
    Other conditions: PCOS
    View official trial listing →
  • Completed NCT NCT03169959

    A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

    Not yet reported AstraZeneca 85 participants Est. completion 2017-08-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03178591

    Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

    Not yet reported Chiang Mai University 43 participants Est. completion 2018-07 1 site
    Type 2 diabetes Other conditions: Ischemic Heart Disease
    View official trial listing →
  • Status unknown NCT NCT03180281

    Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 135 participants Est. completion 2020-01-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03231709

    Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

    Not yet reported Takeda 60 participants Est. completion 2018-02-09 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03249506

    Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

    Janssen Research & Development, LLC 25358 participants Est. completion 2017-11-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03267576

    An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

    Not yet reported Janssen Research & Development, LLC 64 participants Est. completion 2018-10-01 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03310749

    An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers

    Not yet reported Stendhal Americas, S.A. 34 participants Est. completion 2016-05-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03351478

    Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

    Not yet reported Lexicon Pharmaceuticals 770 participants Est. completion 2019-05-16 160 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03363464

    Comparative Effectiveness of Empagliflozin in the US

    Boehringer Ingelheim 230000 participants Est. completion 2026-07-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03430284

    Multifactorial Intervention on Diabetes (MIDiab Study)

    Not yet reported Shandong Provincial Hospital 6300 participants Est. completion 2022-12-31 2 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03433248

    Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

    Not yet reported M.H.H. Kramer 66 participants Est. completion 2022-09-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03458715

    The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

    Not yet reported Mackay Memorial Hospital 120 participants Est. completion 2018-11-21 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03464045

    Empa PASS on Urinary Tract Malignancies

    Boehringer Ingelheim 344995 participants Est. completion 2024-03-11 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03470454

    Contrast Nephropathy in Type 2 Diabetes

    Fayoum University 40 participants Est. completion 2018-11-30 2 sites
    Other conditions: Kidney Function Affection Upon Exposure to Radiocontrast, Diabetes, Microalbuminuria
    View official trial listing →
  • Completed NCT NCT03486964

    Use of Incretins in Diabetic Patients

    University of Pavia 2234 participants Est. completion 2021-05-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03492580

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT03499704

    A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

    Not yet reported Celltrion Pharm, Inc. 133 participants Est. completion 2024-01-16 15 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03500900

    Vildagliptin on Gastric Accommodation

    Not yet reported Universitaire Ziekenhuizen KU Leuven 20 participants Est. completion 2017-01-01 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT03577184

    Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.

    Clinision Est. completion 2019-03
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03602638

    Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

    Not yet reported Chinese PLA General Hospital 300 participants Est. completion 2020-12-01
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03608358

    Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

    Not yet reported AstraZeneca 41 participants Est. completion 2020-08-04 4 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03636763

    Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?

    Assistance Publique Hopitaux De Marseille 183 participants Est. completion 2019-12 1 site
    Other conditions: Bullous Pemphigoid
    View official trial listing →
  • Completed NCT NCT03717194

    Effect of Ertugliflozin on Cardiac Function in Diabetes

    Not yet reported Soo Lim 102 participants Est. completion 2023-04-30 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT03717688

    The Effects of Neprilysin on Glucagon-like Peptide-1

    Not yet reported Nicolai Jacob Wewer Albrechtsen 19 participants Est. completion 2019-05-14 1 site
    Heart failure Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03748810

    Head-to-head Comparison of Empagliflozin and Dapagliflozin

    Chungbuk National University Hospital 600 participants Est. completion 2022-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03751657

    A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

    Not yet reported Novo Nordisk A/S 247 participants Est. completion 2020-01-17 49 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03764631

    Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

    Boehringer Ingelheim 1502 participants Est. completion 2021-01-11 21 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03770052

    Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

    Not yet reported Pusan National University Hospital 159 participants Est. completion 2021-09-13 1 site Stand-alone
    Type 2 diabetes Other conditions: Inadequate Glucose Control
    View official trial listing →
  • Completed NCT NCT03793023

    Observational Study to Evaluate the Efficacy and Safety of Teneligliptin

    Handok Inc. 2983 participants Est. completion 2019-09-23 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03807440

    DIA_CENTRAL:T2D Treatment Pattern in Central Europe

    Boehringer Ingelheim 4083 participants Est. completion 2021-08-31 177 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT03813316

    Approaches To Therapy Escalation In T2D

    Not yet reported LMC Diabetes & Endocrinology Ltd. Est. completion 2019-09-18 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03817463

    A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

    Boehringer Ingelheim 327624 participants Est. completion 2021-12-10 13 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03819127

    Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment

    Not yet reported University of Catania 60 participants Est. completion 2016-09
    Other conditions: Mild Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT03845179

    GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

    Not yet reported University Hospital, Gentofte, Copenhagen 12 participants Est. completion 2020-02-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03877406

    Effect of Empagliflozin on Body Composition and Ketones

    Not yet reported Seoul National University Bundang Hospital 200 participants Est. completion 2023-12-31 1 site
    Other conditions: Diabetes Mellitus, Fat; Intolerance, Pancreas
    View official trial listing →
  • Completed NCT NCT03918148

    Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

    University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03921242

    Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

    Weill Medical College of Cornell University 4888 participants Est. completion 2023-08-01 2 sites
    Type 2 diabetes Other conditions: Renal Insufficiency, Chronic
    View official trial listing →
  • Completed NCT NCT03922750

    A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

    Not yet reported Novo Nordisk A/S 154 participants Est. completion 2020-01-27 38 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03936010

    Replication of the CANVAS Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 152202 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03936049

    Replication of the LEADER Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 168690 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT03939624

    Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

    Canadian Network for Observational Drug Effect Studies, CNODES 419734 participants Est. completion 2019-10-01 1 site
    Type 2 diabetesCardiovascular diseaseHeart failure Other conditions: Cardiovascular Death, All-Cause Mortality
    View official trial listing →
  • Completed NCT NCT03951805

    A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

    Not yet reported Novo Nordisk A/S 205 participants Est. completion 2020-01-17 43 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03983551

    Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

    Not yet reported Changhua Christian Hospital 101 participants Est. completion 2018-02-28
    Type 2 diabetes Other conditions: Proteinuria
    View official trial listing →
  • Completed NCT NCT04013581

    Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

    Not yet reported Yonsei University 121 participants Est. completion 2020-05-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04017221

    Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

    Canadian Network for Observational Drug Effect Studies, CNODES 1249636 participants Est. completion 2019-12-01 1 site
    Type 2 diabetes Other conditions: Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
    View official trial listing →
  • Completed NCT NCT04061473

    Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion

    Not yet reported University Hospital, Gentofte, Copenhagen 20 participants Est. completion 2019-08-20 1 site
    Other conditions: Diabetes After Total Pancreatectomy
    View official trial listing →
  • Completed NCT NCT04124484

    DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 276 participants Est. completion 2019-06-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04161430

    A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 766 participants Est. completion 2022-06-27 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04192292

    Study of Sulphonylurea Synergy With DPP4 Inhibitors

    Not yet reported University of Dundee 30 participants Est. completion 2020-12-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04215523

    Replication of the DECLARE Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 49790 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT04215536

    Replication of the EMPAREG Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 103752 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT04218734

    A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 214 participants Est. completion 2021-06-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04283318

    Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes

    Not yet reported Medical University of Graz 80 participants Est. completion 2022-02-28 1 site
    Type 2 diabetes Other conditions: Healthy, Obesity, Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT04295005

    A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

    Boehringer Ingelheim 24500 participants Est. completion 2021-09-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04304430

    Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors

    University of Padova 11206 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04326166

    Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

    Dong-A ST Co., Ltd. 1971 participants Est. completion 2021-07-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT04410341

    The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

    Not yet reported, Not yet reported Sadat City University Est. completion 2024-12-01 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Terminated NCT NCT04416269

    Oral Anti Diabetic Agents in the Hospital

    Not yet reported Emory University 85 participants Est. completion 2025-04-11 3 sites Added to GLP-1
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT04419337

    Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

    Not yet reported Chang Gung Memorial Hospital 200 participants Est. completion 2024-01-31 1 site
    Cardiovascular disease Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT04469582

    The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors

    University of Athens 113 participants Est. completion 2020-12-31 1 site
    Other conditions: Bullous Pemphigoid
    View official trial listing →
  • Completed NCT NCT04521049

    Tubular Markers in Response to Saxagliptin Therapy

    Not yet reported Beni-Suef University 80 participants Est. completion 2020-04-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04521452

    Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

    Not yet reported Asan Medical Center 218 participants Est. completion 2024-09 1 site
    Other conditions: CAVD
    View official trial listing →
  • Completed NCT NCT04542213

    Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

    Not yet reported Hospital Regional de Alta Especialidad del Bajio 70 participants Est. completion 2021-02-28 1 site
    Other conditions: Hyperglycemia, Covid19
    View official trial listing →
  • Status unknown NCT NCT04626323

    Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease

    Not yet reported Hospital Alemão Oswaldo Cruz 60 participants Est. completion 2024-12 1 site
    Type 2 diabetes Other conditions: Kidney Disease, Chronic, Kidney Injury
    View official trial listing →
  • Completed NCT NCT04654676

    DPP4 Inhibitor on Glycemic Variability

    Not yet reported University Malaysia Sarawak 12 participants Est. completion 2019-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04667143

    Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 760 participants Est. completion 2022-10
    Other conditions: Diabetes Mellitus, Type II
    View official trial listing →
  • Completed NCT NCT04727580

    HSK7653 in Chinese Patients with Impaired Glucose Tolerance

    Not yet reported Haisco Pharmaceutical Group Co., Ltd. 99 participants Est. completion 2022-06-29 1 site
    Prediabetes
    View official trial listing →
  • Completed NCT NCT04735042

    SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

    University of Pisa 60 participants Est. completion 2022-04-07 1 site
    Type 2 diabetes Other conditions: Urinary Tract Infections
    View official trial listing →
  • Status unknown NCT NCT04796428

    GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

    Not yet reported Center for Outcomes Research and Clinical Epidemiology, Italy 1167 participants Est. completion 2023-12-31
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04825795

    DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

    The Catholic University of Korea 4007 participants Est. completion 2021-03-30 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT04976283

    Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

    Not yet reported Getz Pharma 123 participants Est. completion 2023-11-15 1 site
    Type 2 diabetesMASHMASLD
    View official trial listing →
  • Status unknown NCT NCT05032001

    ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

    Not yet reported Metabolic Research Unit 30 participants Est. completion 2022-08-01 1 site
    Type 2 diabetes Other conditions: Abdominal Obesity
    View official trial listing →
  • Status unknown NCT NCT05103306

    Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

    Chungbuk National University Hospital 300 participants Est. completion 2022-12
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05105698

    Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

    Not yet reported LG Chem 28 participants Est. completion 2022-09-30
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT05162690

    Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy

    Not yet reported, Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 40 participants Est. completion 2023-12-31 1 site
    Other conditions: Diabetic Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT05214573

    Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

    Mayo Clinic 386301 participants Est. completion 2025-07-22 1 site
    Type 2 diabetes Other conditions: Cardiac Disease
    View official trial listing →
  • Active, not recruiting NCT NCT05220917

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
    Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
    View official trial listing →
  • Completed NCT NCT05266404

    Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

    Not yet reported AstraZeneca 46 participants Est. completion 2022-05-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05284344

    The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes

    University of Adelaide 78 participants Est. completion 2023-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05290506

    Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

    Not yet reported National University of Malaysia 50 participants Est. completion 2021-03-01 1 site
    PrediabetesType 2 diabetes
    View official trial listing →
  • Completed NCT NCT05313529

    LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

    Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 396 participants Est. completion 2026-07-01 5 sites
    Type 2 diabetes Other conditions: Mild Cognitive Impairment
    View official trial listing →
  • Status unknown NCT NCT05347459

    Cognitive Protective Effect of Newer Antidiabetic Drugs

    Alexandria University 100 participants Est. completion 2023-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05353673

    The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

    Not yet reported Peking University People's Hospital 120 participants Est. completion 2023-02-01 1 site
    Other conditions: Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia, Physiological Effects of Drugs
    View official trial listing →
  • Completed NCT NCT05359341

    Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

    Not yet reported Sadat City University 175 participants Est. completion 2022-01-10 1 site
    Other conditions: Diabete Type 2
    View official trial listing →
  • Status unknown NCT NCT05386186

    The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

    Not yet reported Peking University People's Hospital 192 participants Est. completion 2024-03-31 1 site
    Type 2 diabetes Other conditions: Severe Insulin Deficient Diabetes
    View official trial listing →
  • Status unknown NCT NCT05429554

    The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

    MTI University 60 participants Est. completion 2022-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05578352

    The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

    Not yet reported Nanjing First Hospital, Nanjing Medical University 20 participants Est. completion 2023-01-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05663736

    Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

    Not yet reported Seoul National University Bundang Hospital 80 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Ejection Fraction
    View official trial listing →
  • Completed NCT NCT05755360

    DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

    Novo Nordisk A/S 291 participants Est. completion 2024-10-21 25 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05768945

    Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

    Brigham and Women's Hospital 742670 participants Est. completion 2023-12-31 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Status unknown NCT NCT05817097

    Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

    Ajou University School of Medicine 22119 participants Est. completion 2024-12-30
    Other conditions: Cerebral Infarction, Infarction, Brain, Dipeptidyl-Peptidase IV Inhibitors
    View official trial listing →
  • Status unknown NCT NCT05818995

    Therapeutic Drug Use for CKD Patients

    Qianfoshan Hospital 10000 participants Est. completion 2024-06-30 1 site
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT05870462

    Semaglutide and Vascular Regeneration

    Not yet reported Canadian Medical and Surgical Knowledge Translation Research Group 100 participants Est. completion 2024-12 2 sites Added to GLP-1
    Cardiovascular diseaseType 2 diabetes Other conditions: Atherosclerosis, Obesity
    View official trial listing →
  • Status unknown NCT NCT05902468

    Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Tanta University 88 participants Est. completion 2024-11-28 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05977465

    Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

    Not yet reported, Not yet reported Tanta University 50 participants Est. completion 2023-08-03 1 site
    Other conditions: Diabetic Neuropathy Peripheral
    View official trial listing →
  • Status unknown NCT NCT06010992

    Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

    Not yet reported Tanta University 70 participants Est. completion 2025-01-01 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06021119

    Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

    Not yet reported Ain Shams University 50 participants Est. completion 2023-04-21 1 site
    Other conditions: Time in Range
    View official trial listing →
  • Completed NCT NCT06099067

    Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

    AstraZeneca 239990 participants Est. completion 2023-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06101667

    Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)

    Not yet reported Beijing Tiantan Hospital 224 participants Est. completion 2026-07-01 1 site
    Cardiovascular disease Other conditions: Basilar Artery Occlusion
    View official trial listing →
  • Completed NCT NCT06145360

    Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

    Not yet reported SINA Health Education and Welfare Trust 150 participants Est. completion 2024-03-01 1 site
    Type 2 diabetes Other conditions: Glucose Metabolism Disorders, Hypoglycemic Agents, Empagliflozin
    View official trial listing →
  • Completed NCT NCT06148259

    SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes

    Not yet reported Kasr El Aini Hospital 57 participants Est. completion 2022-09-13 2 sites
    Other conditions: Diabetes Mellitus, Prostatic Hyperplasia
    View official trial listing →
  • Status unknown NCT NCT06164535

    The Effects of DPPIs on Cognitive Function of Diabetic Patients

    Not yet reported Beni-Suef University 105 participants Est. completion 2024-07-15 1 site Stand-alone
    Other conditions: Cognitive Impairment
    View official trial listing →
  • Status unknown NCT NCT06218342

    Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

    Not yet reported Sir Run Run Shaw Hospital 156 participants Est. completion 2025-12-31
    Type 2 diabetes Other conditions: Non-Alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT06263673

    Anti-Diabetic Medications to Fight PD and LBD

    Not yet reported Mayo Clinic 18 participants Est. completion 2025-01-08 1 site
    Other conditions: Lewy Body Dementia, Parkinson Disease
    View official trial listing →
  • Status unknown NCT NCT06301191

    The Effect of Semaglutide on Cardiovascular Markers and Liver Function

    Attikon Hospital 50 participants Est. completion 2024-05-01 1 site
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT06348706

    Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes

    Not yet reported Ain Shams University 60 participants Est. completion 2024-01-15 1 site
    MASH Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Status unknown NCT NCT06449235

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Completed NCT NCT06495281

    Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients

    LG Chem 2044 participants Est. completion 2025-12-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06570980

    Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

    Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 200 participants Est. completion 2024-08-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06611904

    The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

    Not yet reported Attikon Hospital 60 participants Est. completion 2024-12-15 1 site
    Other conditions: Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness
    View official trial listing →
  • Completed NCT NCT06703268

    A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

    Not yet reported Haisco Pharmaceutical Group Co., Ltd. 64 participants Est. completion 2024-11-20 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06770894

    DPP4-Inhibitors and Bone Metabolism in Diabetes

    Not yet reported Azienda Policlinico Umberto I 132 participants Est. completion 2024-01-24 1 site
    Type 2 diabetes Other conditions: Osteoporosis, Bone Loss, Postmenopausal
    View official trial listing →
  • Completed NCT NCT06851962

    Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites
    Type 2 diabetes
    View official trial listing →
  • Enrolling by invitation NCT NCT07073768

    Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

    Not yet reported Khyber Medical College, Peshawar 126 participants Est. completion 2026-12-30 1 site
    Type 2 diabetes Other conditions: Glycemic Control for Diabetes Mellitus
    View official trial listing →
  • Not yet recruiting NCT NCT07108985

    Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

    Not yet reported Yonsei University 100 participants Est. completion 2030-08-31 1 site
    Type 2 diabetes Other conditions: Hyperglycemia, Insulin Resistance
    View official trial listing →
  • Active, not recruiting NCT NCT07198191

    SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

    Yonsei University 200000 participants Est. completion 2026-08-30 1 site
    Cardiovascular diseaseType 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07241897

    DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

    Not yet reported Second Affiliated Hospital of Soochow University 312 participants Est. completion 2028-04-30 1 site
    Cardiovascular disease Other conditions: Diabete Mellitus
    View official trial listing →
  • Completed NCT NCT07332156

    Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

    Samsung Medical Center 21692 participants Est. completion 2023-12-31
    Type 2 diabetes Other conditions: COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)
    View official trial listing →
  • Not yet recruiting NCT NCT07436663

    Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

    Not yet reported Tanta University 150 participants Est. completion 2027-12-01
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT07439536

    Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis

    Not yet reported Kafrelsheikh University 64 participants Est. completion 2025-10-01 1 site
    Other conditions: Liver Cirrhosis With Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07460336

    Effects of Cofrogliptin on Beta-Cell Function in LADA Patients

    Not yet reported Second Xiangya Hospital of Central South University 84 participants Est. completion 2027-12-31 1 site
    Other conditions: Latent Autoimmune Diabetes in Adults (LADA)
    View official trial listing →
  • Not yet recruiting NCT NCT07585526

    Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.

    Not yet reported Institute of Liver and Biliary Sciences, India 160 participants Est. completion 2028-03-31 1 site
    MASLDChronic kidney disease
    View official trial listing →
  • Completed NCT NCT07628556

    Antidiabetic Medications and Risk of Cancer

    University of Pecs 74799 participants Est. completion 2025-12-30 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT07677865

    GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

    West China Hospital 213891 participants Est. completion 2026-06-24 1 site
    Type 2 diabetes Other conditions: Alzheimer Disease, Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07708610

    Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes

    Chung Shan Medical University 71775 participants Est. completion 2026-08-31 1 site Stand-alone
    Type 2 diabetes Other conditions: Pneumonia
    View official trial listing →
  • Enrolling by invitation NCT NCT07713901

    Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

    Novo Nordisk A/S 93600000 participants Est. completion 2026-12-31 1 site
    Other conditions: Medullary Thyroid Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07811011

    Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome

    Not yet reported, Not yet reported Tanta University 70 participants Est. completion 2027-03-30
    Other conditions: Poly Cystic Ovary Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.